BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27196750)

  • 21. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.
    Botta C; Cucè M; Pitari MR; Caracciolo D; Gullà A; Morelli E; Riillo C; Biamonte L; Gallo Cantafio ME; Prabhala R; Mignogna C; Di Vito A; Altomare E; Amodio N; Di Martino MT; Correale P; Rossi M; Giordano A; Munshi NC; Tagliaferri P; Tassone P
    Leukemia; 2018 Apr; 32(4):1003-1015. PubMed ID: 29158557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circular RNA circPSAP functions as an efficient miR-331-3p sponge to regulate proliferation, apoptosis and bortezomib sensitivity of human multiple myeloma cells by upregulating HDAC4.
    Ma H; Shen L; Yang H; Gong H; Du X
    J Pharmacol Sci; 2022 May; 149(1):27-36. PubMed ID: 35369902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
    Mims A; Walker AR; Huang X; Sun J; Wang H; Santhanam R; Dorrance AM; Walker C; Hoellerbauer P; Tarighat SS; Chan KK; Klisovic RB; Perrotti D; Caligiuri MA; Byrd JC; Chen CS; James Lee L; Jacob S; Mrózek K; Bloomfield CD; Blum W; Garzon R; Schwind S; Marcucci G
    Leukemia; 2013 Apr; 27(4):871-8. PubMed ID: 23178755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.
    Cheriyath V; Kuhns MA; Kalaycio ME; Borden EC
    Br J Cancer; 2011 Mar; 104(6):957-67. PubMed ID: 21364585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Double-Negative Feedback Interaction between MicroRNA-29b and DNMT3A/3B Contributes to Ovarian Cancer Progression.
    Teng Y; Zuo X; Hou M; Zhang Y; Li C; Luo W; Li X
    Cell Physiol Biochem; 2016; 39(6):2341-2352. PubMed ID: 27832631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNAs miR-26a, miR-26b, and miR-29b accelerate osteogenic differentiation of unrestricted somatic stem cells from human cord blood.
    Trompeter HI; Dreesen J; Hermann E; Iwaniuk KM; Hafner M; Renwick N; Tuschl T; Wernet P
    BMC Genomics; 2013 Feb; 14():111. PubMed ID: 23418963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.
    Fulciniti M; Amodio N; Bandi RL; Cagnetta A; Samur MK; Acharya C; Prabhala R; D'Aquila P; Bellizzi D; Passarino G; Adamia S; Neri A; Hunter ZR; Treon SP; Anderson KC; Tassone P; Munshi NC
    Blood Cancer J; 2016 Jan; 6(1):e380. PubMed ID: 26771806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miRNA-29b Inhibits Prostate Tumor Growth and Induces Apoptosis by Increasing Bim Expression.
    Sur S; Steele R; Shi X; Ray RB
    Cells; 2019 Nov; 8(11):. PubMed ID: 31752117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
    Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
    Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact.
    Li Z; Wong KY; Calin GA; Chng WJ; Chan GC; Chim CS
    Clin Epigenetics; 2019 May; 11(1):71. PubMed ID: 31064412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
    Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
    BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of miR-29b-3p aggravates podocyte injury by targeting HDAC4 in LPS-induced acute kidney injury.
    Ha ZL; Yu ZY
    Kaohsiung J Med Sci; 2021 Dec; 37(12):1069-1076. PubMed ID: 34369661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
    Chiang CL; Goswami S; Frissora FW; Xie Z; Yan PS; Bundschuh R; Walker LA; Huang X; Mani R; Mo XM; Baskar S; Rader C; Phelps MA; Marcucci G; Byrd JC; Lee LJ; Muthusamy N
    Blood; 2019 Aug; 134(5):432-444. PubMed ID: 31151986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genistein inhibits the proliferation of human multiple myeloma cells through suppression of nuclear factor-κB and upregulation of microRNA-29b.
    Xie J; Wang J; Zhu B
    Mol Med Rep; 2016 Feb; 13(2):1627-32. PubMed ID: 26718793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell Line.
    Kawano M; Tanaka K; Itonaga I; Iwasaki T; Tsumura H
    PLoS One; 2015; 10(9):e0138560. PubMed ID: 26393798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
    Zhou X; Yang XY; Popescu NC
    Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
    Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
    Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing.
    Ahn MY; Kang DO; Na YJ; Yoon S; Choi WS; Kang KW; Chung HY; Jung JH; Min do S; Kim HS
    Cancer Lett; 2012 Dec; 325(2):189-99. PubMed ID: 22781396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.
    Nasser MW; Datta J; Nuovo G; Kutay H; Motiwala T; Majumder S; Wang B; Suster S; Jacob ST; Ghoshal K
    J Biol Chem; 2008 Nov; 283(48):33394-405. PubMed ID: 18818206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.